PMID- 31181859
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 8
IP  - 6
DP  - 2019 Jun 9
TI  - Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired 
      Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
LID - 10.3390/jcm8060824 [doi]
LID - 824
AB  - This study aimed to compare the clinical efficacy and safety of ceftaroline with 
      those of ceftriaxone for treating community-acquired pneumonia (CAP). The PubMed, 
      Cochrane Library, Embase, and clinicalTrials.gov databases were searched until 
      April 2019. This meta-analysis only included randomized controlled trials (RCTs) 
      that evaluated ceftaroline and ceftriaxone for the treatment of CAP. The primary 
      outcome was the clinical cure rate, and the secondary outcome was the risk of 
      adverse events (AEs). Five RCTs were included. Overall, at the test of cure 
      (TOC), the clinical cure rate of ceftaroline was superior to the rates of 
      ceftriaxone for the treatment of CAP (modified intent-to-treat population (MITT) 
      population, odds ratio (OR) 1.61, 95% confidence interval (CI) 1.31-1.99, I(2) = 
      0%; clinically evaluable (CE) population, OR 1.38, 95% CI 1.07-1.78, I(2) = 14%). 
      Similarly, the clinical cure rate of ceftaroline was superior to that of 
      ceftriaxone at the end of therapy (EOT) (MITT population, OR 1.57, 95% CI 
      1.16-2.11, I(2) = 0%; CE population, OR 1.64, 95% CI 1.15-2.33, I(2) = 0%). For 
      adult patients, the clinical cure rate of ceftaroline remained superior to that 
      of ceftriaxone at TOC (MITT population, OR 1.66, 95% CI 1.34-2.06, I(2) = 0%; CE 
      population, OR 1.39, 95% CI 1.08-1.80, I(2) = 30%) and at EOT (MITT population, 
      OR 1.64, 95% CI 1.20-2.24, I(2) = 0%; CE population, OR 1.65, 95% CI 1.15-2.36, 
      I(2) = 0%). Ceftaroline and ceftriaxone did not differ significantly in the risk 
      of serious AEs, treatment-emergent AEs, and discontinuation of the study drug 
      owing to an AE. In conclusion, the clinical efficacy of ceftaroline is similar to 
      that of ceftriaxone for the treatment of CAP. Furthermore, this antibiotic is as 
      tolerable as ceftriaxone.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, Fujian, China. shawnlan0713@gmail.com.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Department of Pharmacy, Chi Mei Medical Center, Liouying 73657, Taiwan. 
      httremoon@ms.szmc.edu.tw.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AUID- ORCID: 0000-0002-6334-2388
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, 
      Taiwan. dtmed141@gmail.com.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian 351100, Fujian, China. 
      jane90467@gmail.com.
FAU - Chao, Chien-Ming
AU  - Chao CM
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, 
      Taiwan. ccm870958@yahoo.com.tw.
LA  - eng
PT  - Journal Article
DEP - 20190609
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC6617040
OTO - NOTNLM
OT  - ceftaroline
OT  - ceftriaxone
OT  - community-acquired pneumonia
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2019/06/12 06:00
MHDA- 2019/06/12 06:01
PMCR- 2019/06/09
CRDT- 2019/06/12 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/06/06 00:00 [revised]
PHST- 2019/06/07 00:00 [accepted]
PHST- 2019/06/12 06:00 [entrez]
PHST- 2019/06/12 06:00 [pubmed]
PHST- 2019/06/12 06:01 [medline]
PHST- 2019/06/09 00:00 [pmc-release]
AID - jcm8060824 [pii]
AID - jcm-08-00824 [pii]
AID - 10.3390/jcm8060824 [doi]
PST - epublish
SO  - J Clin Med. 2019 Jun 9;8(6):824. doi: 10.3390/jcm8060824.